A Randomized, Double-blind, Multicenter Study of Subcutaneous Secukinumab, Assessing Psoriasis Area and Severity Index (PASI) Response and Maintenance of Response in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis on Either a Fixed Dose Regimen or on a Retreatment at Start of Relapse Regimen
A Randomized, Double-blind, Multicenter Study of Subcutaneous Secukinumab, Assessing Psoriasis Area and Severity Index (PASI) Response and Maintenance of Response in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis on Either a Fixed Dose Regimen or on a Retreatment at Start of Relapse Regimen
This study will assess the safety and efficacy of two different doses and two different dose regimens of subcutaneous secukinumab in patients that have moderate to severe, chronic, plaque-type psoriasis.
Inclusion criteria:
Severity of disease meeting all of the following three criteria:
Exclusion criteria:
Pierre-Benite Cédex, F-69495, France
Buchholz I. D. Nordheide, 21244, Germany
Dippoldiswalde-Schmiedeberg, 01744, Germany
Hyderabad, Andhra Pradesh 500 058, India
Secunderabad, Andhra Pradesh 500 094, India
Chiyoda-ku, Tokyo 102-8798, Japan
Itabashi-ku, Tokyo 173-8610, Japan
Minato-ku, Tokyo 105-8471, Japan
Shinjuku-ku, Tokyo 160-0023, Japan
Shinjuku-ku, Tokyo 160-8582, Japan